CN109153676A - Nbi-98854的晶型及其制备方法和用途 - Google Patents
Nbi-98854的晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN109153676A CN109153676A CN201780029517.5A CN201780029517A CN109153676A CN 109153676 A CN109153676 A CN 109153676A CN 201780029517 A CN201780029517 A CN 201780029517A CN 109153676 A CN109153676 A CN 109153676A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- nbi
- solid
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种NBI‑98854(结构如式I所示)的晶型及其制备方法和用途。所述的NBI‑98854晶型分别命名为晶型CS1、晶型CS2,可用于制备治疗迟发性运动障碍的药物。所述的NBI‑98854晶型的溶解度、引湿性符合药用要求,稳定性好,能稳定储存,避免药物在开发过程中发生转晶,从而避免药物溶解度、溶出率、生物利用度以及药效的改变。为含NBI‑98854的药物制剂的制备提供了新的更好的选择,对于药物开发具有非常重要的意义。
Description
PCT国内申请,说明书已公开。
Claims (12)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610488976 | 2016-06-29 | ||
CN2016104889767 | 2016-06-29 | ||
PCT/CN2017/090926 WO2018001335A1 (zh) | 2016-06-29 | 2017-06-29 | Nbi-98854的晶型及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109153676A true CN109153676A (zh) | 2019-01-04 |
CN109153676B CN109153676B (zh) | 2021-08-10 |
Family
ID=60785885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780029517.5A Active CN109153676B (zh) | 2016-06-29 | 2017-06-29 | Nbi-98854的晶型及其制备方法和用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10442800B2 (zh) |
EP (1) | EP3473623B1 (zh) |
CN (1) | CN109153676B (zh) |
ES (1) | ES2811048T3 (zh) |
WO (1) | WO2018001335A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101553487A (zh) * | 2006-11-08 | 2009-10-07 | 纽罗克里生物科学有限公司 | 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法 |
WO2015120110A2 (en) * | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
WO2015171802A1 (en) * | 2014-05-06 | 2015-11-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
WO2018067945A1 (en) * | 2016-10-06 | 2018-04-12 | Assia Chemical Industries Ltd. | Solid state forms of valbenazine |
WO2018130345A1 (en) * | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3102239A1 (en) * | 2014-02-07 | 2016-12-14 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
AU2018242134B2 (en) * | 2017-04-01 | 2023-09-28 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
-
2017
- 2017-06-29 WO PCT/CN2017/090926 patent/WO2018001335A1/zh unknown
- 2017-06-29 US US16/311,754 patent/US10442800B2/en not_active Expired - Fee Related
- 2017-06-29 CN CN201780029517.5A patent/CN109153676B/zh active Active
- 2017-06-29 ES ES17819332T patent/ES2811048T3/es active Active
- 2017-06-29 EP EP17819332.2A patent/EP3473623B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101553487A (zh) * | 2006-11-08 | 2009-10-07 | 纽罗克里生物科学有限公司 | 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法 |
WO2015120110A2 (en) * | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
WO2015171802A1 (en) * | 2014-05-06 | 2015-11-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
WO2018067945A1 (en) * | 2016-10-06 | 2018-04-12 | Assia Chemical Industries Ltd. | Solid state forms of valbenazine |
WO2018130345A1 (en) * | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
Non-Patent Citations (2)
Title |
---|
ANON: ""A crystalline form of L-valine (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester"", 《IP.COM JOURNAL》 * |
ANON: ""Novel preparation of crystalline forms L1 and L2 of L-valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester"", 《IP.COM JOURNAL》 * |
Also Published As
Publication number | Publication date |
---|---|
ES2811048T3 (es) | 2021-03-10 |
US10442800B2 (en) | 2019-10-15 |
EP3473623B1 (en) | 2020-07-15 |
EP3473623A4 (en) | 2019-06-12 |
CN109153676B (zh) | 2021-08-10 |
US20190218209A1 (en) | 2019-07-18 |
WO2018001335A1 (zh) | 2018-01-04 |
EP3473623A1 (en) | 2019-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105111215B (zh) | 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法 | |
WO2016165650A1 (zh) | 奥拉帕尼与尿素的共晶及其制备方法 | |
CN108884111A (zh) | 克立硼罗游离形式的晶型及其制备方法和用途 | |
CN109219597A (zh) | 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法 | |
KR20170132251A (ko) | 3,5-2치환 벤젠알키닐 화합물의 결정 | |
CN109153656A (zh) | 他发米帝司葡甲胺盐的晶型e及其制备方法和用途 | |
CN110128356A (zh) | 一种吉非替尼与3-羟基苯甲酸共晶体 | |
CN105732575A (zh) | 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法 | |
CN109400598B (zh) | 盐酸小檗碱与乳酸共晶、其制备方法和应用 | |
CN109548403A (zh) | Galunisertib的晶型及其制备方法和用途 | |
CN109153676A (zh) | Nbi-98854的晶型及其制备方法和用途 | |
CN108329308A (zh) | 一种二氢嘧啶类化合物的固体形式及其制备方法 | |
WO2015113370A1 (zh) | 一种甜菊糖a苷晶体及其制备方法和用途 | |
CN114644642B (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
CN104961681B (zh) | 卡博替尼的粘酸盐及其晶型 | |
CN108794383B (zh) | 硝苯地平与异烟酰胺的共晶 | |
CN106279151A (zh) | 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法 | |
CN107721902A (zh) | 阿普斯特与烟酰胺的共结晶及其制备方法和应用 | |
CN105037391B (zh) | 一种头孢孟多酯钠化合物及其制剂 | |
US20210002307A1 (en) | Crystal Forms of Crisaborole In Free Form And Preparation Method And Use Thereof | |
CN104884128B (zh) | 力格赛狄盐及其晶型、它们的制备方法和用途 | |
CN109153677A (zh) | Plx3397的盐酸盐晶型及其制备方法和用途 | |
CN105949183B (zh) | 阿齐沙坦酯的晶型及其制备方法 | |
CN110036003A (zh) | Ap26113的新晶型及其制备方法 | |
CN106794179A (zh) | 马赛替尼甲磺酸盐的新晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |